Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040428 · ClinicalTrials.gov registry record · Phase 3
The Fibrin Pad CV Phase III Study
A Phase 3 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
NCT02040428 is a Phase 3 study that has completed, run by Ethicon. The registered enrollment target is 156 participants.
The verdict
NCT02040428, a Phase 3 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.
Interventions
- BIOLOGICAL Topical hemostat
- BIOLOGICAL EVARREST™ Fibrin Sealant Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2015-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040428
The ClinicalTrials.gov registry entry for NCT02040428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ethicon, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topical hemostat is the first listed.
NCT02040428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02040428 about?
NCT02040428 is a clinical study titled "The Fibrin Pad CV Phase III Study". The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.
What is the current status of trial NCT02040428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2014-01-01. Estimated completion is 2015-09-01.
What interventions are being tested in trial NCT02040428?
The interventions under investigation include: Topical hemostat (BIOLOGICAL), EVARREST™ Fibrin Sealant Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT02040428?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.